复星医药(02196.HK)：子公司“重酒石酸去甲肾上腺素注射液”药品注册申请获药监局批准

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of a new drug, heavy tartrate norepinephrine injection, which is indicated for acute hypotensive states and other critical conditions [1] Group 1 - The approved drug is indicated for restoring blood pressure in acute hypotensive states, assisting in treatment during cardiac arrest, and maintaining blood pressure post-cardiac arrest [1] - The drug can also be used as an auxiliary treatment for shock due to insufficient blood volume, helping to temporarily maintain cerebral and coronary perfusion until volume resuscitation takes effect [1] - The drug is classified as a Class 3 chemical drug and is produced by Jinzhou Aohong Pharmaceutical [1]